Stock BDSX BIODESIX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Biodesix, Inc.

Equities

BDSX

US09075X1081

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
1.45 USD +2.84% Intraday chart for Biodesix, Inc. -7.94% -21.20%
May. 13 TD Cowen Starts Biodesix With Buy Rating, $2.80 Price Target MT
May. 08 Transcript : Biodesix, Inc., Q1 2024 Earnings Call, May 08, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Biodesix to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting
AQ
Biodesix to Present New Data on the Nodify XL2® Test at ATS 2024 Annual Meeting
BU
TD Cowen Starts Biodesix With Buy Rating, $2.80 Price Target
MT
Transcript : Biodesix, Inc., Q1 2024 Earnings Call, May 08, 2024
Biodesix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (BDSX) BIODESIX Reports Q1 Revenue $14.8M, vs. Street Est of $14.2M
MT
Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management
BU
Biodesix to Participate in the 2024 RBCCM Global Healthcare Conference
BU
Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024
BU
Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting
BU
Biodesix, Inc. announced that it has received $34.999422 million in funding
CI
Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement
AQ
Top Midday Decliners
MT
Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement
BU
Biodesix, Inc. announced that it expects to receive $34.999422 million in funding
CI
Biodesix Strikes New Research Deal With Memorial Sloan Kettering Cancer Center
MT
Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center
BU
Biodesix Announces New Master Collaborative Research Agreement with Memorial Sloan Kettering Cancer Center
CI
Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights
AQ
Transcript : Biodesix, Inc., Q4 2023 Earnings Call, Mar 01, 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BDSX Stock
  4. News Biodesix, Inc.